Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

610
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
610
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

2.6K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Nanopore sequencing with proteins: synchronization and dischronization of molecular dynamics simulations with laboratory and industrial developments.

Soft matter·2026
Same author

Identification of Immune-Related Diagnostic Genes and Subtypes of Active Ulcerative Colitis.

Iranian journal of allergy, asthma, and immunology·2026
Same author

Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer.

British journal of cancer·2026
Same author

Slow Dissociation of Nitazenes from the <i>μ</i>-Opioid Receptor Underlies the Challenge of Overdose Reversal.

bioRxiv : the preprint server for biology·2026
Same author

Specific GPCRs elicit unique extracellular vesicle miRNA array signatures.

eLife·2026
Same author

Proteogenomic characterization delineates clinically relevant subtypes of advanced differentiated thyroid cancer.

Cell reports. Medicine·2026
Same journal

Neuroprotective in vitro effects of histone deacetylase 6-selective inhibitor SW-100 toward oxaliplatin-derived toxicity.

Molecular pharmacology·2026
Same journal

Emerging roles of platelet DNA in cancer detection and noninvasive prenatal testing.

Molecular pharmacology·2026
Same journal

Binding affinities for histamine receptors 1 to 4: Systematic comparison of ligands from the Psychoactive Drug Screening Program K<sub>i</sub> database and International Union of Basic and Clinical Pharmacology/British Pharmacological Society Guide to Pharmacology.

Molecular pharmacology·2026
Same journal

Molecular pharmacology of mGlu<sub>7/8</sub> heterodimers reveals unique properties of orthosteric agonists and positive allosteric modulators.

Molecular pharmacology·2026
Same journal

Effects of ivermectin on the activation and desensitization of the human GABA<sub>A</sub> receptor.

Molecular pharmacology·2026
Same journal

Corrigendum to "Amantadine derivative Amt-1 enhances antiviral defense against influenza A virus via Nrf2/HO-1 pathway" [Molecular Pharmacology 108 (2026) 100099].

Molecular pharmacology·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Sep 10, 2025

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

13.9K

Los agonistas del receptor 1 asociado a las trazas de aminas regulan diferencialmente la función del transportador de

Julia K Huey1, Xiao Shi2, William E Schutzer3

  • 1Program in Physiology and Pharmacology, Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon; Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon.

Molecular pharmacology
|August 21, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los agonistas del receptor 1 asociado a las trazas de aminas (TAAR1) muestran efectos variados sobre el transportador de dopamina (DAT). Las diferencias en la forma en que estos agonistas TAAR1 afectan la función y el tráfico de DAT son clínicamente relevantes para el diseño terapéutico.

Palabras clave:
Las anfetaminasEl transportador de la dopaminaReceptor asociado a las trazas de aminas 1

Más Videos Relacionados

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.9K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

13.9K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.9K

Área de la Ciencia:

  • La neurociencia
  • Farmacología

Sus antecedentes:

  • Los agonistas del receptor 1 asociado a las trazas de aminas (TAAR1), incluido el ulotaront, se han investigado para los trastornos neuropsiquiátricos.
  • La eficacia clínica antipsicótica de Ulotaront fue similar a la de placebo en ensayos de fase III, lo que plantea dudas sobre los mecanismos de los agonistas de TAAR1.

Objetivo del estudio:

  • Investigar la farmacología de los agonistas TAAR1 RO5166017, RO5256390 y ulotaront en el transportador de dopamina (DAT).
  • Para probar la hipótesis de que diferentes agonistas TAAR1 tienen efectos distintos en la función DAT y la homeostasis de la dopamina.

Principales métodos:

  • Se evaluó la unión directa e inhibición de la absorción de dopamina en el DAT para RO5166017, RO5256390, y ulotaront.
  • Evaluación de los efectos dependientes de TAAR1 sobre la absorción de dopamina y el eflujo de dopamina inducido por la anfetamina en células cultivadas y sinaptosomas de roedores.
  • Se utilizó la biotinilación superficial para medir los cambios en los niveles de DAT en la superficie celular.

Principales resultados:

  • RO5166017 y RO5256390 inhiben directamente la absorción de dopamina a través del DAT, mientras que el ulotaront no lo hace.
  • RO5166017 aumentó la absorción de dopamina, mientras que ulotaront y RO5256390 la redujeron, de una manera dependiente de TAAR1.
  • RO5166017 aumento de la DAT de la superficie celular y el eflujo de dopamina inducido por la anfetamina, efectos dependientes de la activación de TAAR1.

Conclusiones:

  • Existen diferencias clínicamente relevantes en los efectos directos y mediados por TAAR1 de los agonistas TAAR1 sobre el DAT.
  • Cada agonista (RO5166017, RO5256390, ulotaront) mostró un perfil farmacológico único en el DAT.
  • Estos distintos mecanismos deben considerarse en el diseño terapéutico y la aplicación clínica de los agonistas TAAR1.